<a href="https://www.fiercebiotech.com/biotech/protagonist-opts-475m-takeda-instead-splitting-us-rusfertide-profits" hreflang="en">Protagonist opts for $475M in Takeda payouts instead of splitting US rusfertide profits</a>
Protagonist Therapeutics has opted to receive $475 million from Takeda instead of splitting U.S. profits for rusfertide, a drug aimed at treating polycythemia vera, following its successful phase 3 study and FDA submission. This decision allows Protagonist to secure immediate cash and potential future milestone payments while maintaining a strong partnership with Takeda.
Protagonist Therapeutics' decision to opt for a $475 million payout from Takeda instead of a 50/50 U.S. profit split for the near-approval drug rusfertide highlights a strategic move to secure non-dilutive cash while maintaining long-term economic gains through milestone payments and global royalties. This approach not only reduces immediate financial risk but also strengthens Protagonist's ability to invest in its pipeline, a valuable consideration for stakeholders in healthtech and biotech investment.